Table 5.

Sensitivity Analysis on Percentages of Adults With and Without Diabetes Mellitus and ASCVD₁₀ ≥7.5%^a Taking High‐ and Moderate‐Intensity Statins

Variable Statin Eligible Group	Sample, n	Population, N	Statin Intensity	∅Statin ASCVD10, %	∅Statin ASCVD10, n	⊕Statin ASCVD10, n	Change ASCVD10 Events, n	ASCVD10 RRR, %	ASCVD10 ARR, %	NNT
100% Moderate‐intensity statin
⊕DM ASCVD10 ≥7.5%b	273	5 435 130	Moderate	20.3	1 102 617	814 563	288 504	28.8	5.3	19
∅DM ASCVD10 ≥7.5%c	589	16 022 464	Moderate	13.5	2 161 319	1 450 004	711 316	34.3	4.4	23
75% Moderate‐, 25% high‐intensity statin
⊕DM ASCVD10 ≥7.5%b	273	5 435 130	Moderate‐high	20.3	1 102 617	782 347	320 270	32.0	5.9	17
∅DM ASCVD10 ≥7.5%c	589	16 022 464	Moderate‐high	13.5	2 161 319	1 374 589	786 730	37.9	4.9	20
50% Moderate‐ and 50% high‐intensity statin
⊕DM ASCVD10 ≥7.5%b	273	5 435 130	Moderate‐high	20.3	1 102 617	751 566	351 051	35.0	6.5	15
∅DM ASCVD10 ≥7.5%c	589	16 022 464	Moderate‐high	13.5	2 161 319	1 303 415	857 905	41.3	5.4	19
25% Moderate‐ and 75% high‐intensity
⊕DM ASCVD10 ≥7.5%b	273	5 435 130	Moderate‐high	20.3	1 102 617	722 149	380 468	37.8	7.0	14
∅DM ASCVD10 ≥7.5%c	589	16 022 464	Moderate‐high	13.5	2 161 319	1 228 995	932 324	44.8	5.8	17
100% High‐intensity statin
⊕DM ASCVD10 ≥7.5%b	273	5 435 130	High	20.3	1 102 617	694 028	408 588	40.5	7.5	13
∅DM ASCVD10 ≥7.5%c	589	16 022 464	High	13.5	2 161 319	1 172 783	988 536	47.5	6.2	16

ASCVD indicates atherosclerotic cardiovascular disease; NNT, number needed‐to‐treat.

^aParticipants with (⊕) and without (∅) diabetes mellitus (DM) and 10‐year ASCVD risk (ASCVD₁₀) <7.5% have an indication only for moderate‐intensity statins and were excluded. Participants with ASCVD and LDL ≥190 have an indication for high‐intensity statins and were excluded.

^bOnly participants with (⊕) diabetes mellitus (DM) who also had ASCVD₁₀ ≥7.5% were included.

^cOnly participants without (∅) DM and ASCVD₁₀ ≥7.5% were included.